Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

Foligain foam caused severe scalp irritation and flakiness, unlike Rogaine foam. The user plans to consult a dermatologist for treatment options.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

A user is experiencing increased hair shedding after using a homemade topical finasteride mixture with stemoxydine for six weeks. They are concerned about whether the low dose could cause shedding so early.

KX-826 stopped hair loss for the user after stopping finasteride due to mild side effects. The user experienced mild headaches initially with KX-826, which resolved after a few days.

The user is considering switching from topical finasteride to RU58841 or KX826 due to side effects like low libido and ED. They are also using oral minoxidil and considering low-dose saw palmetto to maintain their hairline.

A user tried a Korean hair loss shampoo and treatment set, noting it improved scalp and hair quality but lacked ingredient details. Other users expressed skepticism about its effectiveness, suggesting it might not significantly impact hair loss.

A 26-year-old had 2,060 grafts transplanted in Bogotá, Colombia, and is using oral Minoxidil 2.5mg twice daily. They are not using Finasteride.

A user is considering using topical finasteride, topical minoxidil, RU58841, and dermarolling twice a week to address hair loss after experiencing side effects with oral finasteride. They previously saw positive results with a topical spray containing finasteride, minoxidil, and tretinoin but discontinued use due to laziness.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions an update on Dr. Bloxham's Verteporfin treatment.

Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.

The conversation discusses experiences with mixing KY19382 with PEG400 or other mixtures for hair loss treatment. It also mentions interest in a group purchase of KY19382 or other hair loss research powders.

The user is considering switching from topical finasteride to RU58841 or KX826 to reduce side effects but decides to stick with finasteride for now. Users discuss the effectiveness and risks of RU58841 and KX826, with finasteride being considered the most reliable option.

A user is attempting to reformulate a topical gel using PP-405 for hair loss, aiming to enhance its effectiveness with additional compounds. They discuss the potential of PP-405 compared to other treatments like Minoxidil and GT20029, and emphasize the importance of proper formulation for efficacy.

PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.

The user is experiencing hair regrowth using 1.2 mg oral finasteride and 3 mg oral minoxidil after aggressive balding. They express concerns about hair loss affecting confidence and consider additional treatments like dutasteride.

The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

A 23-year-old has been using finasteride every other day and topical minoxidil daily for five months to address hair thinning, with plans to resume dermarolling. They experienced minimal shedding and are considering switching to daily finasteride for better results.

The user has accepted their hair loss and uses finasteride and minoxidil, with past use of RU58841 and dutasteride. They seek advice on supplements to slow down graying hair.

Hair loss treatments are advancing, with Coegin Pharma's FOL005 expected this year and Breezula potentially later. Pyrilutamide is available but not very effective, while Kintor's products face skepticism; traditional treatments like finasteride and minoxidil remain dominant.

The conversation discusses a botanically derived treatment for androgenetic alopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.

Fibrin hydrogels, when combined with stem cells, can induce hair follicle regeneration and show potential for treating alopecia. The study demonstrated successful hair growth in mice without adverse effects.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

A 37-year-old is starting topical finasteride for hair loss, with lab results showing normal hormone levels. They plan to avoid further research initially and may share future lab results if significant side effects occur.

The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.

Topical finasteride in a liposomal formulation reduces systemic absorption compared to ethanol solutions. The user is seeking sources for such products, noting that popular options like morr-f are not liposomal.

Hair cell therapy and follicle cloning are still in experimental stages, with treatments like hair multiplication and regenerative hair therapy being marketed but not yet proven to create unlimited new follicles. There is skepticism about the effectiveness and legitimacy of these treatments, with some considering them scams.

The user has been using finasteride and minoxidil for hair loss but experienced worsening temple recession. They suspect they might be more sensitive to testosterone and are considering trying RU58841 or CB 03 01 as additional treatments.